Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Blood (2017) 130 (Supplement 1): 4013.

https://doi.org/10.1182/blood.V130.Suppl_1.4013.4013

Published: 2017

Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Blood (2017) 130 (Supplement 1): 2745.

https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study

Michael J. Dickinson, MBBS, FRACP, FRCPA, Honor Cherif, Pierre Fenaux, Moshe Mittleman, Amit Verma, MD, Maria Socorro O Portella, MD, Paul Burgess, Uwe Platzbecker, MD

Blood (2016) 128 (22): 163.

https://doi.org/10.1182/blood.V128.22.163.163

Published: 2016

Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD

Blood (2016) 128 (22): 5223.

https://doi.org/10.1182/blood.V128.22.5223.5223

Published: 2016

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Michael J. Dickinson, MBBS, FRACP, FRCPA, Kirsten Herbert, MD BSci(MD, FRACP, PhD, Caroline Sardjono, MDPhD, Thao Le, MDPhD, Diana Zannino, BSc, MSc, Colin Wood, John F Seymour, MBBS, FRACP, PhD, Melita Kenealy, MD, Miles Prince, MD FRACP, FRCPA

Blood (2014) 124 (21): 4657.

https://doi.org/10.1182/blood.V124.21.4657.4657

Published: 2014

Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Blood (2014) 124 (21): 116.

https://doi.org/10.1182/blood.V124.21.116.116

Published: 2014

Journal Articles

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

Michael J. Dickinson, MBBS, FRACP, FRCPA, Alexander Davenport, Pasquale Petrone, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Paul Neeson, PhD

Blood (2013) 122 (21): 3495.

https://doi.org/10.1182/blood.V122.21.3495.3495

Published: 2013

Journal Articles

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, Anupkumar George, MBBS FRACP FRCPA, Michael S Hofman, MBBS FRACP FAANMS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MBBS, FRACP, FRCPA, PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, John F. Seymour, MBBS, FRACP, PhD

Blood (2013) 122 (21): 1796.

https://doi.org/10.1182/blood.V122.21.1796.1796

Published: 2013

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP

Blood (2012) 120 (21): 2652.

https://doi.org/10.1182/blood.V120.21.2652.2652

Published: 2012

Journal Articles

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Paul Neeson, PhD, Amit S Khot, MBBS, MD, MRCP, FRCPath, Stefan Peinert, MD, Tsin Y Tai, MSc, Karen Chen, Kellie Tainton, BSc, Dominic Wall, PhD, Dirk Hoenemann, MD, Michael H Kershaw, PhD, Jennifer Westwood, Joe Trapani, PhD, Mark J Smyth, PhD, Phillip Darcy, PhD, Andrew Scott, PhD, Lucy Kravets, BSc, Jill Davison, RN, Michael J. Dickinson, MBBS, FRACP, FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2011) 118 (21): 4180.

https://doi.org/10.1182/blood.V118.21.4180.4180

Published: 2011

Journal Articles

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Michael J. Dickinson, MBBS, Rosemary Hoyt, BN, Andrew Roberts, MBBS PhD, Andrew Grigg, MBBS, John Francis Seymour, MBBS PhD, Jeff Szer, MBBS BSc BMedSci, H. Miles Prince, MBBS(Hons)MD, David Ritchie, MBChB PhD

Blood (2007) 110 (11): 5115.

https://doi.org/10.1182/blood.V110.11.5115.5115

Published: 2007

NARROW

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only